PleoPharma, Inc. Secures $36 Million to Combat Cannabis Withdrawal Issues
PleoPharma, Inc. Secures $36 Million in Series B Financing
PleoPharma, Inc., a company dedicated to addressing health issues linked to cannabis use, recently announced the successful closure of a $36 million Series B financing round. This significant investment will accelerate the development of their leading asset, PP-01, which is being positioned as a pioneering treatment for those suffering from Cannabis Use Disorder (CUD).
As the first and only treatment designated as Fast Track for mitigating cannabis withdrawal symptoms, PP-01 has entered Phase 3 trials. Data from the Substance Abuse and Mental Health Services Administration (SAMHSA) reveals that a staggering 20.6 million Americans engaged with cannabis and exhibited signs of dependency as of 2024. The growing prevalence of cannabis addiction highlights an urgent need for effective solutions, particularly as there are currently no FDA-approved medications addressing this condition.
Ginger Constantine, MD, co-founder and CEO of PleoPharma, emphasized the company’s commitment to aid the large number of individuals grappling with this disorder.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.